Cargando…
The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620255/ http://dx.doi.org/10.1186/1129-2377-14-S1-P200 |
| _version_ | 1782265560559517696 |
|---|---|
| author | Silberstein, S Dodick, DW DeGryse, RE Lipton, R Turkel, CC |
| author_facet | Silberstein, S Dodick, DW DeGryse, RE Lipton, R Turkel, CC |
| author_sort | Silberstein, S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3620255 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Springer |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36202552013-09-20 The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program Silberstein, S Dodick, DW DeGryse, RE Lipton, R Turkel, CC J Headache Pain Poster Presentation Springer 2013 2013-02-21 /pmc/articles/PMC3620255/ http://dx.doi.org/10.1186/1129-2377-14-S1-P200 Text en Copyright ©2013 Silberstein et al; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Silberstein, S Dodick, DW DeGryse, RE Lipton, R Turkel, CC The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program |
| title | The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program |
| title_full | The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program |
| title_fullStr | The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program |
| title_full_unstemmed | The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program |
| title_short | The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program |
| title_sort | percent of chronic migraine patients who responded to onabotulinumtoxina treatment per treatment cycle in the preempt clinical program |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620255/ http://dx.doi.org/10.1186/1129-2377-14-S1-P200 |
| work_keys_str_mv | AT silbersteins thepercentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT dodickdw thepercentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT degrysere thepercentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT liptonr thepercentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT turkelcc thepercentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT silbersteins percentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT dodickdw percentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT degrysere percentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT liptonr percentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram AT turkelcc percentofchronicmigrainepatientswhorespondedtoonabotulinumtoxinatreatmentpertreatmentcycleinthepreemptclinicalprogram |